Wall Street analyst price targets, ratings consensus & upside potential
Last 12 months price action with 12-month analyst target path
As of February 28, 2026, Precision BioSciences, Inc. (DTIL) has a Wall Street consensus price target of N/A, based on estimates from 0 covering analysts. The company has a market capitalization of $51M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is N/A, with 0 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, DTIL trades at a trailing P/E of 4.0x.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how DTIL stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus price target for DTIL is $N/A, close to the current price of $4.2 (N/A% implied move). Based on 0 analyst estimates, the stock appears fairly valued near current levels.
DTIL has a consensus rating of "N/A" based on 0 Wall Street analysts. The rating breakdown is mixed, with 0 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
DTIL's current price is $4.2 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $N/A for DTIL, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
DTIL is lightly followed, with 0 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 0 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month DTIL stock forecast based on 0 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "N/A".
DTIL appears fairly valued according to analysts, with a "N/A" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
DTIL analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.